Deletion of ribosomal protein genes is a common vulnerability in human cancer, especially in concert with TP53 mutations. Issue 4 (6th March 2017)

• Record Type: Journal Article
• Authors: Ajore, Ram; Raiser, David; McConkey, Marie; Jöud, Magnus; Boidol, Bernd; Mar, Brenton; Saksena, Gordon; Weinstock, David M; Armstrong, Scott; Ellis, Steven R; Ebert, Benjamin L; Nilsson, Björn
• Is Part Of: EMBO molecular medicine. Volume 9:Issue 4(2017)
• Page Start: 498
• Page End: 507
• Publication Date: 2017-03-06
• Subjects: cancer -- ribosomal gene haploinsufficiency -- ribosome function; Molecular biology -- Periodicals; Medical genetics -- Periodicals; Pathology, Molecular -- Periodicals; 616.04205
• DOI: 10.15252/emmm.201606660
• Languages: English
• ISSNs: 1757-4676

Abstract

Abstract: Heterozygous inactivating mutations in ribosomal protein genes (RPGs) are associated with hematopoietic and developmental abnormalities, activation of p53, and altered risk of cancer in humans and model organisms. Here we performed a large‐scale analysis of cancer genome data to examine the frequency and selective pressure of RPG lesions across human cancers. We found that hemizygous RPG deletions are common, occurring in about 43% of 10, 744 cancer specimens and cell lines. Consistent with p53‐dependent negative selection, such lesions are underrepresented in TP53 ‐intact tumors ( P ≪ 10 −10 ), and shRNA‐mediated knockdown of RPGs activated p53 in TP53 ‐wild‐type cells. In contrast, we did not see negative selection of RPG deletions in TP53 ‐mutant tumors. RPGs are conserved with respect to homozygous deletions, and shRNA screening data from 174 cell lines demonstrate that further suppression of hemizygously deleted RPGs inhibits cell growth. Our results establish RPG haploinsufficiency as a strikingly common vulnerability of human cancers that associates with TP53 mutations and could be targetable therapeutically. Synopsis: Hemizygous deletion of ribosomal protein genes (RPGs) is a strikingly common vulnerability of human cancers that associates with TP53 mutations and could be targetable therapeutically. Heterozygous inactivating mutations in ribosomal protein genes (RPGs) have previously been associated with hematopoietic and developmental abnormalities, activation of p53, and altered risk of cancer in humans and model organisms. Large‐scale analysis of cancer genome data revealed that hemizygous RPG deletions occur in about 43% of 10, 744 cancer specimens and cell lines. Consistent with p53‐dependent negative selection, such RPG deletions are underrepresented in TP53 ‐intact tumors, but not in TP53 ‐mutant tumors. RPGs are conserved with respect to homozygous deletions, and further suppression of hemizygously deleted RPGs inhibits cell growth. Abstract : Hemizygous deletion of ribosomal protein genes (RPGs) is a strikingly common vulnerability of human cancers that associates with TP53 mutations and could be targetable therapeutically.